Chronic Kidney DiseasesUMPMR-VNCT07869849
A Minute for my Kidneys
A study testing Dialysis in people with Chronic Kidney Diseases, run by GCS Ramsay Santé pour l'Enseignement et la Recherche at 1 site in France.
Trial summary
The purpose of this study is to evaluate the effectiveness of the "One Minute for My Kidneys" program in reducing the time it takes for participants with stage V chronic kidney disease and other comorbidities to begin dialysis. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Chronic Kidney Diseases
- What is being tested?
- Dialysis
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 312 participants
- Where
- 1 siteFrance
- Study dates
- Nov 2026to Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 and ≤ 80;
- Participants with stage V chronic kidney disease;
- Participants with documented type 2 diabetes AND/OR documented glomerular disease (proteinuria > 1 g/24 h) AND/OR diagnosed with heart failure as recognized by a cardiologist according to the criteria of the European Society of Cardiology;
- Participants who have and agree to use an internet connection;
- Participants who speak and understand French and are able to complete the questionnaires;
- Participants who have been informed and have signed an informed consent form;
- Participants covered by a social security program.
Who cannot join
- Inability to use the app (blindness, severe intellectual disability);
- Life expectancy of less than 6 months, as determined by the investigator;
- Significant noncompliance, as determined by the investigator;
- Participants for whom, in the event of end-stage renal disease, palliative care would be chosen over dialysis or transplantation;
- Women who are pregnant or may become pregnant (of childbearing age and not using effective contraception) or who are breastfeeding;
- Persons under legal guardianship (under legal protection or deprived of liberty by judicial or administrative decision);
- A person unable to understand the information related to the study (due to linguistic, psychological, cognitive, or other reasons);
- A participant currently enrolled in another clinical trial or study, or who has participated in another clinical trial or study that could have affected their health status within the 6 months prior to enrollment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Hôpital Privé La Louvière
Lille, 59800
Maxime HOFFMANN, MD, maxime.hoffmann@gmail.com
About this study
Official title: A Minute for my Kidneys - Stadium V
The purpose of this study is to evaluate the effectiveness of the "One Minute for My Kidneys" program in reducing the time it takes for participants with stage V chronic kidney disease and other comorbidities to begin dialysis.
Read the detailed description
This is a multicenter, interventional, prospective, randomized, controlled, open-label clinical investigation.
The study population is composed of adults with stage V chronic kidney disease and other comorbidities.
Participants are offered enrollment in the clinical trial during a nephrology follow-up visit for their chronic kidney disease. Participants who are enrolled after signing an informed consent form and confirming their eligibility will then be randomized to either the group receiving access to the "1 Minute for My Kidneys" program in addition to standard of care, or the group receiving standard of care alone.
- Conditions
- Chronic Kidney Diseases
- Being tested
- Dialysis
- Medical subject headings
- Renal Insufficiency, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DialysisDrug
Dialysis for a patient with stage V chronic kidney disease
| Study group | Role | What they receive |
|---|---|---|
| "1 Minute for My Kidneys" App | Experimental | Participants in the experimental group will be monitored, in addition to receiving standard care, using the "1 Minute for My Kidneys" app.
In addition, they will be required to complete a quality-of-life questionnaire (EQ-5D-5L, available directly in the app) once every 3 months. Receives: Drug: Dialysis |
| Control group with quality of life | Active comparator | In addition to their usual care, participants in the control group will be asked to complete a questionnaire on quality of life during their nephrology appointment once every three months. Receives: Drug: Dialysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to initiation of dialysis
Time to initiation of dialysis (scheduled and unscheduled) for participants with stage V chronic kidney disease and one or more comorbidities.
Measured: Up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2026
- Study startNov 2026 (estimated)
- Primary completionDec 2029 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney DiseasesStudies of the same condition, open and under way.
- More trials run by GCS Ramsay Santé pour l'Enseignement et la RechercheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A multicenter, interventional, prospective, randomized, controlled clinical investigation
- Masking
- None (open label)
- Enrolment
- 312 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Euraxi Pharma
- Responsible party
- Sponsor
- Investigators
- Maxime HOFFMANN, Principal investigator, Hôpital Privé La Louvière
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07869849
- Sponsor's protocol ID
- 2025-A00771-48
- Acronym
- UMPMR-V
- Status last verified
- Oct 2026
- First submitted
- 2 Oct 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Minute for my Kidneys - Stadium V
- ClinicalTrials.gov ID
- NCT07869849
- Acronym / sponsor ID
- UMPMR-V / 2025-A00771-48
- Conditions
- Chronic Kidney Diseases
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 312 participants (estimated)
- Lead sponsor
- GCS Ramsay Santé pour l'Enseignement et la RechercheUniversity, hospital or other
- Collaborators
- Euraxi Pharma
- Study start
- Nov 2026 (estimated)
- Primary completion
- Dec 2029 (estimated)
- Study completion
- Dec 2029 (estimated)
- First posted
- 13 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effectiveness of the "One Minute for My Kidneys" program in reducing the time it takes for participants with stage V chronic kidney disease and other comorbidities to begin dialysis.
Detailed description
This is a multicenter, interventional, prospective, randomized, controlled, open-label clinical investigation.
The study population is composed of adults with stage V chronic kidney disease and other comorbidities.
Participants are offered enrollment in the clinical trial during a nephrology follow-up visit for their chronic kidney disease. Participants who are enrolled after signing an informed consent form and confirming their eligibility will then be randomized to either the group receiving access to the "1 Minute for My Kidneys" program in addition to standard of care, or the group receiving standard of care alone.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- A multicenter, interventional, prospective, randomized, controlled clinical investigation
| Arm | Type | Receives |
|---|---|---|
| "1 Minute for My Kidneys" App | Experimental | Drug: DialysisParticipants in the experimental group will be monitored, in addition to receiving standard care, using the "1 Minute for My Kidneys" app. In addition, they will be required to complete a quality-of-life questionnaire (EQ-5D-5L, available directly in the app) once every 3 months. |
| Control group with quality of life | Active comparator | Drug: DialysisIn addition to their usual care, participants in the control group will be asked to complete a questionnaire on quality of life during their nephrology appointment once every three months. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥ 18 and ≤ 80;
- Participants with stage V chronic kidney disease;
- Participants with documented type 2 diabetes AND/OR documented glomerular disease (proteinuria > 1 g/24 h) AND/OR diagnosed with heart failure as recognized by a cardiologist according to the criteria of the European Society of Cardiology;
- Participants who have and agree to use an internet connection;
- Participants who speak and understand French and are able to complete the questionnaires;
Key exclusion criteria (8 listed)
- Inability to use the app (blindness, severe intellectual disability);
- Life expectancy of less than 6 months, as determined by the investigator;
- Significant noncompliance, as determined by the investigator;
- Participants for whom, in the event of end-stage renal disease, palliative care would be chosen over dialysis or transplantation;
- Women who are pregnant or may become pregnant (of childbearing age and not using effective contraception) or who are breastfeeding;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DialysisDialysis for a patient with stage V chronic kidney disease | Drug | "1 Minute for My Kidneys" App, Control group with quality of life |
Primary outcome
Time to initiation of dialysis
Time frame: Up to 24 months
Time to initiation of dialysis (scheduled and unscheduled) for participants with stage V chronic kidney disease and one or more comorbidities.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
Related trials for Chronic Kidney Diseases
Not yet recruiting
Comparative Feasibility and Effectiveness of Medically Tailored Meals Approaches for Pediatric End-Stage Kidney Disease
End Stage Kidney Disease (ESKD)
RecruitingPhase 2
UBT251 Injection Phase II Clinical Study (CKD)
Obesity &Amp; Overweight, Chronic Kidney Disease
RecruitingObservational study
Kidney Stiffness Measured by Ultrasound in Patients With High Blood Pressure and Healthy Volunteers
Arterial Hypertension, Chronic Kidney Disease, Primary Aldosteronism
Active, not recruiting
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Bladder Cancer, Prostate Cancer
RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Atherosclerosis, Cardiovascular Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Maxime HOFFMANN principal investigator
Hôpital Privé La Louvière
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dialysis in people with Chronic Kidney Diseases, run by GCS Ramsay Santé pour l'Enseignement et la Recherche at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maxime HOFFMANN, MD (6 86 70 91 23 ext. +33, maxime.hoffmann@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to initiation of dialysis (time frame: Up to 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.